Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Bioinform.

Sec. Drug Discovery in Bioinformatics

Network-based insights into miR-30a-5p-mediated regulation and EGCG targeting in triple-negative breast cancer

Provisionally accepted
  • School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India

The final, formatted version of the article will be published soon.

Background: Triple-negative breast cancer (TNBC) is defined by the absence of ER, PR, and HER2 expression. This limits the targeted therapies, resulting in poor clinical outcomes. Identifying the molecular targets that can be regulated through miRNAs and natural compounds offers a potential therapeutic platform. Methods: We combined transcriptomic profiling with miRNA target prediction to identify genes regulated by miR-30a-5p and assess their interaction with the green tea polyphenol, epigallocatechin gallate (EGCG). Differentially expressed genes (DEGs) from TCGA-TNBC datasets and miRNA targets from miRDB, TargetScan, and miRTarBase were screened for common genes. Then, the protein-protein interaction and network topology analyses were performed to identify key hub genes. Molecular docking and simulation were carried out with the four key genes against EGCG. Results: Data integration yielded 393 overlapping genes and identified ten hub genes- RRM2, KIF11, ANLN, CDC20, CCNA1, AGO2, YWHAZ, DTL, SKP2, and PCNA. Pathway enrichment showed that all these hubs are involved in cell cycle and mitotic regulation, which was associated with poor TNBC prognosis. Mutation profiling revealed high alteration rates in KIF11, ANLN, CDC20, and YWHAZ, with increased missense mutations and C>T transitions. Molecular docking and simulations identified YWHAZ as the most favorable and structurally stable EGCG-binding target, compared to the other three key genes. Conclusion: The results emphasizes that EGCG has strong binding affinity towards YWHAZ, revealing that miR-30a-EGCG targets TNBC synergistically through cell-cycle-mediated pathways. The findings give rational support for miRNA-guided phytochemical-based TNBC therapeutic development.

Keywords: Network Pharmacology, TNBC, Hsa-miR-30a-5p, EGCG, cell cycle regulation, molecular docking, Molecular Dynamics Simulation

Received: 29 Oct 2025; Accepted: 27 Nov 2025.

Copyright: © 2025 Dharshini and Mandal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Abul Kalam Azad Mandal

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.